HUB Organoids for Drug Development
In Vitro Screening with PDO and PDXO
CrownBio has entered into an exclusive partnership with Hubrecht Organoid Technology (HUB) to provide preclinical drug development and validation services using HUB organoid technology and the HUB tumor organoid biobank.
HUB Biobank Organoids
CrownBio’s HUB Organoid Services are expected to be available by late 2019! This highly translational in vitro screening platform includes the development of patient-derived organoids (PDO), as well as PDX-derived organoids (PDXO) from CrownBio’s extensive patient-derived xenograft (PDX) collection.
HUB Organoid Models Currently In Development
HUB’s adult stem cell-derived organoids, originally developed in the Clevers Lab are generated using highly standardized, proprietary culture methods. The organoids faithfully recapitulate tumors in patients and are extensively characterized by pathology, genomics, and sensitivity to known and experimental drugs.
Help Us Build The Optimum Organoids Service Portfolio
Your input will help us to build the most useful preclinical platform, and prioritize model development. We greatly appreciate your participation in our quick 2 minute survey.
Join the Organoids Mailing List
To receive the most up to date information on CrownBio's Organoid Service development, simply complete the the form to the right. You'll receive the latest information, news, and content about organoids and HUB organoids.
What Are Organoids
The term organoids is currently used to signify 3D cell-based models derived from adult, embryonic, or induced pluripotent stem cells which are maintained in vitro to give rise to mini-organs.
Organoids represent the only in vitro technology to faithfully recapitulate original tissue physiology, providing a fast and cost-effective model for applications such as drug development and tissue engineering.